BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025
Commercial Progress:
BridgeBio Pharma has reported significant commercial progress for its recently FDA-approved drug Attruby, with 430 prescriptions written by 248 unique physicians for ATTR-CM treatment since its approval in November 2024123.
Pipeline Updates: The company has completed enrollment in three major Phase 3 clinical trials:
FORTIFY (112 patients for LGMD2I/R9), CALIBRATE (70 patients for ADH1), and PROPEL 3 (114 participants for achondroplasia). These trials are expected to reach significant milestones in the second half of 2025123.
Financial Position:
BridgeBio has a strong financial position with $406 million in cash as of last quarter, plus $500 million received upon Attruby's FDA approval from a royalty facility. The company anticipates an additional $105 million in regulatory milestones in the first half of 2025 from expected European and Japanese approvals of acoramidis123.
Market Competition:
Attruby's approval sets up a potential three-way race in the transthyretin amyloid cardiomyopathy (ATTR-CM) market between Pfizer’s tafamidis (Vyndaqel and Vyndamax) and Alnylam’s Amvuttra5.
Pricing:
BridgeBio intends to price Attruby at $18,759.12 for a 28-day supply, equating to approximately $244,500 per year5.
Analyst Reaction:
Analysts have hailed Attruby's debut as a 'launch to own', with BMO Capital Markets analyst Kostas Biliouris noting that the approval with a label reflecting cardiovascular mortality renders it similar to Tafamidis, representing a bull case scenario5.
Sources:
1. https://www.stocktitan.net/news/BBIO/bridge-bio-announces-commercial-progress-program-updates-and-2025-2zphb7ztj26m.html
2. https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-commercial-progress-program-updates-and-2025
3. https://www.globenewswire.com/news-release/2025/01/13/3008704/0/en/BridgeBio-Announces-Commercial-Progress-Program-Updates-and-2025-Milestones.html
5. https://www.biospace.com/drug-development/attr-cm-approval-for-bridgebio-could-trigger-tight-race-with-pfizer